Call for Abstract
Submission Deadline
November 24, 2026
Type of Presentation
・Primary Session
・Oral Session（oral or digital poster）
| Session | Abstract Language | Presentation Language | Slide Language | Video Use |
|---|---|---|---|---|
| Symposium | Japanese | Japanese | Japanese/English | Permitted |
| President’s Requested Symposium（1-1、1-2、2-2、3-1） | Japanese | Japanese | English | Permitted |
| Panel Discussion | Japanese | Japanese | Japanese/English | Permitted |
| General Presentations | Japanese | Japanese | Japanese/English | Permitted |
| Overseas Joint Session:Case Conference | English | English | English | Permitted |
President’s Requested Symposium
| Symposium 1-1 |
Current Status and Future Perspectives of Endovascular Treatment for Aortic Arch Aneurysms |
|---|---|
| Symposium 1-2 |
Early Clinical Outcomes and Technical Tips for Commercially Available Branched Stent-Graft for Thoracoabdominal Aortic Aneurysms in Japan |
| Symposium 1-3 |
Development of Novel Surgical Techniques and Medical Devices in Vascular Surgery Field |
| Symposium 1-4 |
Strategies for Preventing Cerebral Infarction During EndovascularTreatment of Aortic Arch Aneurysms |
| Symposium 1-6 |
Treatment of Chronic Aortic Dissection: Outcomes and Limitations of Open versus Endovascular Repair |
| Symposium 2-2 |
Regional and Institutional Approaches to Acute Aortic Syndromes in Japan |
| Symposium 2-3 |
The Last Bastion of Open Surgery: Indications and Evolution of Open Thoracoabdominal Repair in the Endovascular Era |
| Symposium 3-1 |
Revascularization stretegy for CLTI: Proposing an Optimal Treatment Algorithm in the BEST-CLI Era |
Advanced Session
■Symposium
| Symposium 2-1 |
Management of Aneurysm Sac Enlargement After EVAR:Criteria for Re-intervention and Strategies |
|---|---|
| Symposium 2-4 |
Education and Succession of Open Surgical Techniques for AAA: Institutional Approaches to Training Young Vascular Surgeons |
| Symposium 2-5 |
Surgical Treatment Strategies for Extensive Aortic Aneurysms: Extending from the Aortic Arch to the Descending Aorta |
| Symposium 2-6 |
State-of-the-Art LEAD Interventions in the SFA and Below-the-Knee Region: Optimal Use of Novel Devices and Key Considerations |
| Symposium 3-2 |
Endpoints of Revascularization in CLTI: Defining "No-Option CLTI" |
| Symposium 3-3 |
Latest Treatment Strategies for SFA EVT with a focus on Long-Term Outcomes |
| Symposium 3-4 |
AI and Data Science in Vascular Surgery: AI Technologies for Daily Clinical Practice |
| Symposium 4-1 |
Treatment of Acute Limb Ischemia: Institutional Strategies and Optimal Endpoints |
| Symposium 4-2 |
DVT Treatment Flontiers: The Latest Strategies for the Prevention and Management of PTS |
| Symposium 4-3 |
Task Shifting in Vascular Surgery: Institutional Initiatives and current situation |
| Symposium 5-1 |
Optimal Management of Aortic Aneurysm Surgery with Concomitant Aortic Root or Arch Lesions |
| Symposium 5-2 |
Treatment Strategies for Acute Type A Aortic Dissection: Aiming for Better Long-Term Outcomes Through Lifelong Management |
| Symposium 5-3 |
Side Branch Embolization during EVAR: Defining Which Branches Should Be Embolized for Preventing Endoleaks |
■Panel Discussion
| Panel Discussion 1-1 |
Preemptive TEVAR with a focus on Long-Term Outcomes: Cervical Branch Revascularization and the Optimal Landing Zone |
|---|---|
| Panel Discussion 1-2 |
Reconsidering Treatment strategy of PRAAA: Alternatives to Commercially Available Branched Stent Grafts -The role of OSR, PMEG, and Snorkel Techniques- |
| Panel Discussion 3-1 |
Mycotic AAA: Institutional Treatment Strategies and Perioperative Management Protocols |
| Panel Discussion 3-2 |
Selection for Surgical and Endovascular Revascularization for Acute Limb Ischemia |
| Panel Discussion 3-3 |
Managing CLTI in Dialysis Patients: Considering the Limits of Revascularization and Wound healing |
| Panel Discussion 5-2 |
Current Updates in the Treatment of Varicose Veins |
Call for Abstracts
| Overseas Joint Session:Case Conference |
Case conference with vascular surgeons from overseas：Regrettable case, Nightmare case, Great save case |
|---|
General Presentations
| 1 |
Thoracic aortic disease |
|---|---|
| 2 |
Thoracoabdominal aortic disease |
| 3 |
Abdominal arota-Iliac artery disease |
| 4 |
Acute aortic dissection (Stanford A) |
| 5 |
Acute aortic dissection (Stanford B) |
| 6 |
Subacute aortic dissection |
| 7 |
Chronic aortic dissection |
| 8 |
Ruptured aortic aneurysm |
| 9 |
Aorto-enteric / Aorto-bronchial fistula |
| 10 |
Mycotic / Inflammatory aortic disease |
| 11 |
Carotid artery disease |
| 12 |
Visceral artery disease |
|---|---|
| 13 |
Peripheral arterial disease (ALI) |
| 14 |
Peripheral arterial disease (claudication) |
| 15 |
Peripheral arterial disease (CLTI) |
| 16 |
Venous disease |
| 17 |
Dialysis access |
| 18 |
Basic research |
| 19 |
Basic research (AI-related) |
| 20 |
Vascular nursing |
| 21 |
Allied health professionals |
| 22 |
Resident/Student Session |
■Presenters at the JSVS Annual Meeting are required to be JSVS members.
If the presenting author is not yet a member at the time of abstract submission, please enter “99999” as a provisional membership number and proceed with the submission step.
■Provided that the presenting author is a JSVS member, co-authors are not required to hold JSVS membership. Please proceed with the registration accordingly.
- ・For program scheduling purposes, you may be asked to present in a format different from the one you selected at the time of submission. We appreciate your understanding in advance.
- ・Among abstracts not accepted for an Advanced Session, those for which the presenter selected “Submit as a General Presentation” under the option “Would you like your abstract to be considered for a General Presentation if it is not accepted for an Advanced Session?” will be reviewed again for acceptance as a General Presentation.
- ・The presentation format for General Presentations (oral or poster) will be determined by the Congress President based on the evaluations by the Program Committee.
Disclosure of Conflict of Interest (COI)
All first authors are required to declare whether they have any conflicts of interest during the period from three years prior to the abstract submission until the time of the presentation, regardless of whether such conflicts exist.
In addition, the COI status must be disclosed on the presentation day.
Acceptance/Rejection of the Abstract
The congress organizer will decide whether to accept or reject the abstract.
The acceptance will be notified by March, along with the presentation style (oral or digital poster). Please note that the congress organizer will make the final allocation of the accepted abstracts.